131 related articles for article (PubMed ID: 38861145)
1. Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis.
Garzanova LA; Ananyeva LP; Koneva OA; Desinova OV; Starovoytova MN; Ovsyannikova OB; Shayakhmetova RU; Glukhova SI
Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861145
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
3. Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
Wang H; Zhou J; Li Y; Wei L; Xu X; Zhang J; Yang K; Wei S; Zhang W
Ther Adv Neurol Disord; 2021; 14():17562864211056710. PubMed ID: 34950240
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease.
Narváez J; Robles-Pérez A; Molina-Molina M; Vicens-Zygmunt V; Luburich P; Yañez MA; Alegre JJ; Nolla JM
Semin Arthritis Rheum; 2020 Oct; 50(5):902-910. PubMed ID: 32906025
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Wang Y; Li L
Int J Rheum Dis; 2023 Feb; 26(2):225-235. PubMed ID: 36378118
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.
Narváez J; Pirola JP; LLuch J; Juarez P; Nolla JM; Valenzuela A
Autoimmun Rev; 2019 Mar; 18(3):262-269. PubMed ID: 30639647
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression.
Narváez J; LLuch J; Molina-Molina M; Vicens-Zygmunt V; Luburich P; Yañez MA; Nolla JM
Semin Arthritis Rheum; 2020 Oct; 50(5):977-987. PubMed ID: 32911289
[TBL] [Abstract][Full Text] [Related]
14. Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis.
Brogan P; Yeung RSM; Cleary G; Rangaraj S; Kasapcopur O; Hersh AO; Li S; Paripovic D; Schikler K; Zeft A; Bracaglia C; Eleftheriou D; Pordeli P; Melega S; Jamois C; Gaudreault J; Michalska M; Brunetta P; Cooper JC; Lehane PB;
Arthritis Rheumatol; 2022 Jan; 74(1):124-133. PubMed ID: 34164952
[TBL] [Abstract][Full Text] [Related]
15. Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.
Moazedi-Fuerst FC; Lackner A; Kreuzer SM; Eller K; Odler B; Kovacs G; Flick H; Talakic E; Hermann J; Venhoff N; Venhoff A; Hafner F; Brodmann M; Jud P; Yazdani-Biuki B; Husic R; Salmhofer W; Stradner MH; Graninger WB; Thiel J; Brezinschek HP
J Autoimmun; 2024 May; 147():103246. PubMed ID: 38788540
[TBL] [Abstract][Full Text] [Related]
16. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
[TBL] [Abstract][Full Text] [Related]
19. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
20. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
